Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Oral AB680 in Healthy Volunteers
NCT04575311Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of quemliclustat in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and prostate cancer (PCa) (2 arms), sponsored by Arcus Biosciences. Primary endpoints: Peak Plasma Concentration at 15 Days, Time of Peak Concentration at 15 Days and 1 more. Started Oct 2020; status: completed.
02
Drugs
quemliclustat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04575311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575311.